• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-Device Combinations

8 drug delivery innovations you need to know

February 25, 2021 By Sean Whooley

Drug Delivery Innovations you need to know

The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Hydrogels, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Research & Development, Respiratory, Technology Tagged With: dyvebioscience, Enable Injections, evoxtherapeutics, Inovio Pharmaceuticals, Johns Hopkins, Lyra Therapeutics, Medtronic, Tandem Diabetes Care, Teva, Teva Pharmaceuticals, Teva Respiratory

Axonics acquires Contura and its Bulkamid bulking agent for $235M

February 25, 2021 By Sean Whooley

Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural closing pressure […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Hydrogels, Mergers & Acquisitions, Pharmaceuticals, Women's Health Tagged With: Axonics Modulation Technologies, Contura

Lilly to add Welldoc app to future insulin pen

February 25, 2021 By Nancy Crotti

Eli Lilly

Eli Lilly (NYSE:LLY) and Welldoc announced a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin pens, which are in development. Lilly and Welldoc will create a new version of Welldoc’s BlueStar insulin management software, which will integrate insulin dosing data for several Lilly insulins. The BlueStar app has FDA 510(k) clearance for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: Eli Lilly & Co., elililly, welldoc

Kala Pharmaceuticals slides on missed Q4 projections

February 25, 2021 By Sean Whooley

Kala Pharmaceuticals - updated logo

Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for the three months ended Dec. 31, 2020, for a more than $10 million bottom-line slide on sales growth […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat

Tandem Diabetes Care skyrockets after hours on Street-beating Q4

February 24, 2021 By Sean Whooley

Tandem Diabetes Care

Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. The San Diego-based insulin delivery and […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Tandem Diabetes Care

Insulet rises on Street-beating Q4 revenues

February 24, 2021 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

B. Braun Medical appoints new CFO

February 23, 2021 By Sean Whooley

B. Braun Medical announced today that it appointed James Allen as a senior VP and as the company’s chief financial officer. Allen, a veteran of more than 30 years in finance and management within multiple industries and disciplines, will replace Bruce Heugel, who last year announced that he would retire after more than 20 years at […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management Tagged With: B. Braun Medical, Personnel, Personnel Moves

Re-Vana Therapeutics appoints new COO, VP of R&D

February 23, 2021 By Sean Whooley

Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D. Belfast, Northern Ireland-based Re-Vana’s two new executives are set to help the company develop its sustained-release therapies for ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma, according to a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Personnel, Personnel Moves, Re-Vana Therapeutics

Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment

February 23, 2021 By Sean Whooley

Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: opioids, peartherapeutics

Global wearable patch market growing at 10.6% rate

February 22, 2021 By Sean Whooley

G6

Researchers say that the global wearable patch market size is expected to reach $12.6 billion by 2026, marking a massive rise over five years. According to the research, put together by ResearchAndMarkets.com, the rise is expected to represent a compound annual growth rate of 10.6% during the forecast period. Wearables covered by the research, including […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: abbott, Dexcom, Eli Lilly & Co., Insulet, sanofi, wearables

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 192
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS